Prader-Willi Syndrome (PWS) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) – Pipeline Review, H1 2017’, provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS)

The report reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Prader-Willi Syndrome (PWS) therapeutics and enlists all their major and minor projects

The report assesses Prader-Willi Syndrome (PWS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Prader-Willi Syndrome (PWS)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alize Pharma SAS

Essentialis Inc

INSYS Therapeutics Inc

LG Chem, Ltd.

Saniona AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Prader-Willi Syndrome (PWS) - Overview

Prader-Willi Syndrome (PWS) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Prader-Willi Syndrome (PWS) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development

Alize Pharma SAS

Essentialis Inc

INSYS Therapeutics Inc

LG Chem, Ltd.

Saniona AB

Prader-Willi Syndrome (PWS) - Drug Profiles

(metoprolol + tesofensine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-531 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BSN-175 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carbetocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diazoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diazoxide choline CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Eutropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAL-671 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Glycogen Synthase for Prader-Willi Syndrome and Glycogen Storage Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prader-Willi Syndrome (PWS) - Dormant Projects

Prader-Willi Syndrome (PWS) - Discontinued Products

Prader-Willi Syndrome (PWS) - Product Development Milestones

Featured News & Press Releases

Nov 07, 2016: Saniona Plans To Initiate Phase 2A Study In Prader-Willi In 2017

Jul 20, 2016: Kalytera Therapeutics Presents New Data Demonstrating KAL671 Ability to Prevent Bone Loss in a Prader-Willi Syndrome Animal Model

Jul 18, 2016: Alize Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences

Jul 05, 2016: Kalytera Therapeutics to Present New Data That Supports the Continued Investigation of KAL671 for the Treatment of Osteoporosis in Prader-Willi Syndrome at the IPWSO Conference

Apr 26, 2016: Alize Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome

Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome

Sep 24, 2015: FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome

Jun 04, 2015: Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies

Mar 02, 2015: Alize Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Prader-Willi Syndrome (PWS) – Pipeline by Alize Pharma SAS, H1 2017

Prader-Willi Syndrome (PWS) – Pipeline by Essentialis Inc, H1 2017

Prader-Willi Syndrome (PWS) – Pipeline by INSYS Therapeutics Inc, H1 2017

Prader-Willi Syndrome (PWS) – Pipeline by LG Chem, Ltd., H1 2017

Prader-Willi Syndrome (PWS) – Pipeline by Saniona AB, H1 2017

Prader-Willi Syndrome (PWS) – Dormant Projects, H1 2017

Prader-Willi Syndrome (PWS) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports